| For: | Yao LT, Wang MZ, Wang MS, Yu XT, Guo JY, Sun T, Li XY, Xu YY. Neoadjuvant endocrine therapy: A potential strategy for ER-positive breast cancer. World J Clin Cases 2019; 7(15): 1937-1953 [PMID: 31423426 DOI: 10.12998/wjcc.v7.i15.1937] |
|---|---|
| URL: | https://www.wjgnet.com/2307-8960/full/v7/i15/1937.htm |
| Number | Citing Articles |
| 1 |
Tingting Wei, Xia Li, Wanmin Qiang, Yan Zhang, Hailing Ren, Qiupeng Zhang, Xue Jin. Menopausal symptoms in breast cancer patients receiving adjuvant endocrine therapy and their relationships with health-promoting behaviors and social support. Menopause 2023; 30(3) doi: 10.1097/GME.0000000000002130
|
| 2 |
Shurui Wang, Difei Huang, Xiaofeng Liu, Qiang Tang, Chenxi Xi, Yixin Ma, Huan Liu, Xing Chen, Aomei Shen, Maojun Di, Wanmin Qiang, Xian Du. Development and validation of a prediction model for frailty in breast cancer patients with extended survival. Supportive Care in Cancer 2024; 32(6) doi: 10.1007/s00520-024-08501-7
|
| 3 |
M. A. Dzhelialova, A. E. Zolotukhina, A. V. Shalaev, R. V. Donskikh, P. V. Krivorotko, A. V. Malek. The challenge of evaluating the efficacy of neoadjuvant endocrine therapy in breast cancer and potential solutions: a literature review. Medical alphabet 2026; (15) doi: 10.33667/2078-5631-2026-15-26-34
|
| 4 |
Huayao Li, Chundi Gao, Qing Liang, Cun Liu, Lijuan Liu, Jing Zhuang, Jing Yang, Chao Zhou, Fubin Feng, Changgang Sun. Cryptotanshinone Is a Intervention for ER-Positive Breast Cancer: An Integrated Approach to the Study of Natural Product Intervention Mechanisms. Frontiers in Pharmacology 2021; 11 doi: 10.3389/fphar.2020.592109
|
| 5 |
Ryeo-Eun Go, Cho-Won Kim, Sung-Moo Lee, Hong Kyu Lee, Kyung-Chul Choi. Fenhexamid induces cancer growth and survival via estrogen receptor-dependent and PI3K-dependent pathways in breast cancer models. Food and Chemical Toxicology 2021; 149 doi: 10.1016/j.fct.2021.112000
|
| 6 |
Yi Li, Kexin Wang, Yupeng Chen, Jieqi Cai, Xuemei Qin, Aiping Lu, Daogang Guan, Genggeng Qin, Weiguo Chen. A System Pharmacology Model for Decoding the Synergistic Mechanisms of Compound Kushen Injection in Treating Breast Cancer. Frontiers in Pharmacology 2021; 12 doi: 10.3389/fphar.2021.723147
|
| 7 |
Nandini Dey, Jennifer Aske, Pradip De. Targeted Neoadjuvant Therapies in HR+/HER2−Breast Cancers: Challenges for Improving pCR. Cancers 2021; 13(3) doi: 10.3390/cancers13030458
|